Dr Lal Pathlabs share price today

Dr Lal Pathlabs Ltd's share price was ₹1,966.80 at the close on 5 November 2026. It has been rising for 23 weeks. That is 13.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,308 and ₹2,005, and at that close it sat 95% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Dr Lal Pathlabs Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 19 weeks in a row.

Over the last 11 years the share price moved +356% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit grew again in the June 2026 quarter and highest quarterly profit in 15 quarters.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹798 crore, +19.1% on a year earlier.

   Why: Revenue rose because each patient paid more, helped by higher prices under the CGHS and ECHS health schemes and a better mix of tests and regions.

   From the earnings call on 24 Jul 2026.

2. Profit grew again in the June 2026 quarter

   Profit was ₹170 crore, +26.9% on a year earlier (₹134 crore), after 2 quarters of decline.

   Why: Profit rose because sales grew and more of each rupee of sales stayed as profit after higher CGHS and ECHS prices.

   Next results: check if the CGHS and ECHS price benefit still lifts margin for another two quarters, or if the company spends it on growth.

   From the earnings call on 24 Jul 2026.

3. Highest quarterly profit in 15 quarters

   Profit of ₹170 crore in the June 2026 quarter is the highest of the last 15 quarters.

   Why: Profit hit a record because sales grew and more of each rupee of sales stayed as profit, helped by higher CGHS and ECHS prices.

   Next results: check whether profit stays high after the fever season, since management will reassess the revenue and margin outlook after Q2.

   From the earnings call on 24 Jul 2026.

For July to September 2026 (the quarter ended 30 September 2026), Dr Lal Pathlabs reported revenue of ₹874 crore, up 19.6% from ₹731 crore a year earlier, and a profit of ₹194 crore, up 27.6% from ₹152 crore.

Dr Lal Pathlabs results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 24 July 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Dr Lal Pathlabs closed at ₹1,966.80 on 5 November 2026, up 27.0% from ₹1,548.35 a year earlier (7 November 2025) and up 8.1% over five years. Its highest weekly close since March 2016 was ₹2,058.70 on 9 September 2021.

Dr Lal Pathlabs share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 5 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 11 March 2016 to 5 November 2026.

11 Nov 2026: Coming up: ex-date for an interim dividend of ₹5 a share. 5 Nov 2026: Dr Lal Pathlabs closed at ₹1,966.80, up 3.2% on the week and up 1.7% on the month.

Earlier

• Results for July to September 2026: Revenue up 19.6% and profit up 27.6% on a year earlier.
• Our read, 22 Aug 2026: The 31% Q1 margin includes CGHS/ECHS pass-through expected for another two quarters and management still retains a 27-28% full-year margin framework.
• 30 Jul 2026: ex-date for an interim dividend of ₹5 a share.
• 24 Jul 2026: Dr Lal Pathlabs held its results call for April to June 2026. Management guided: Planned sustainable revenue growth over the medium term, supported by structural volumes, footprint expansion, specialized tests and pricing headroom.
• 25 Jun 2026: ex-date for a dividend of ₹4 a share, record date 26 Jun 2026.
• 5 Feb 2026: ex-date for an interim dividend of ₹3.50 a share.

Our read of the business

The 31% Q1 margin includes CGHS/ECHS pass-through expected for another two quarters and management still retains a 27-28% full-year margin framework.

Latest quarter: Revenue rose 19.1% on a year earlier to ₹798 crore; operating margin reached 31% with volume, mix and CGHS/ECHS realization support.

Our read after the latest results, written 22 August 2026.

Dr Lal Pathlabs paid ₹16 a share in regular dividends in the 12 months to 5 November 2026 (4 payments), a yield of 0.81% at the ₹1,966.80 close on 5 November 2026. The last was an interim dividend of ₹5 a share, ex-date 30 July 2026. Next: ₹5 a share, ex-date 11 November 2026.

Dr Lal Pathlabs dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 1 of the last 12 months' payments came before a split or bonus; the 12-month total above is on today’s share count.

Yes. Dr Lal Pathlabs Ltd paid out 68% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 24 July 2026, Dr Lal Pathlabs' management guided: Planned sustainable revenue growth over the medium term, supported by structural volumes, footprint expansion, specialized tests and pricing headroom.

“FY27 is for us a year of execution, scaling what we have already built, and deepening our reach into new markets, including rural.”Dr. Arvind Lal, on the call for April to June 2026

What management guided

• FY27 patient volume growth of 6.0-7.0% remains the starting view; Q1 was ahead, but management deferred an updated full-year assessment until after Q2 or H1.
• FY27 revenue growth is more likely to be in the mid-teens than the early teens after Q1; the 27.0-28.0% operating margin framework was not upgraded and will be reviewed after H1.
• CGHS and ECHS pricing should contribute 2.0-3.0% at the overall company level for at least another 2-3 quarters, with margin pass-through expected for another two quarters.
• Swasthfit growth around 20.0% is expected to remain sustainable for some more time, supported by traction in Tier 2 and Tier 3 markets.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 24 July 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

What is changing at Dr Lal Pathlabs, from the latest results and calls: network infrastructure maturation and patient volume acceleration, cghs/echs realization pass-through and swasthfit premiumization and suburban west region rebound and lims integration.

• Network Infrastructure Maturation and Patient Volume Acceleration. April to June 2026 patient volume reached 8.2 million, up 8.2% on a year earlier, after the network additions cited by management. ⚠ estimate
• CGHS/ECHS Realization Pass-Through and Swasthfit Premiumization. CGHS/ECHS contributed 2.0-3.0% to realization and Swasthfit grew around 20.0%, helping revenue per patient reach ₹968. ⚠ estimate
• Suburban West Region Rebound and LIMS Integration. Suburban moved close to double-digit growth after business and LIMS integration. ⚠ estimate
• Digital Automation and Scientific Portfolio Expansion. The company launched 716 tests and reports routine-test turnaround within three hours for almost 90% of walk-in patients. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 22 August 2026.

Patient-volume growth falls below 5.0% for two consecutive quarters.

Each change stops working if

• Network Infrastructure Maturation and Patient Volume Acceleration: Patient-volume growth falls below 5.0% for two consecutive quarters.
• CGHS/ECHS Realization Pass-Through and Swasthfit Premiumization: The CGHS/ECHS benefit annualizes without sustained patient volume or test-mix support.
• Suburban West Region Rebound and LIMS Integration: West-region growth weakens or integration friction returns.
• Digital Automation and Scientific Portfolio Expansion: Specialized-test adoption fails to translate into sustained mix or volume.

The main risks

• Management Guidance Revisions and Goal Consistency: FY27 capital spending rose from ₹100-120 Cr and one to two centers in April to ₹140-150 Cr and potentially three to four centers in July. ✓ fact
• CGHS Realization Taper and Deferred Retail Price Increases: The 2.0-3.0% CGHS/ECHS contribution is expected for another two to three quarters while general price increases remain deferred. ✓ fact
• Capital Allocation to Extended-Payback Radiology and International Assets: FY27 capital spending is ₹140-150 Cr with potentially three to four radiology centers while international business remains below 5% of revenue. ✓ fact
• Institutional Flow Divergence: FII ownership fell 496 basis points while DII ownership rose 534 basis points between Dec 2024 and Sep 2025. ✓ fact

Our read after the latest results, written 22 August 2026.

When Dr Lal Pathlabs reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Q2 patient-volume growth should clarify whether the 8.2% Q1 outcome is sustainable beyond weather and fever-season effects versus the 6.0-7.0% starting-year view.

Dr Lal Pathlabs is on 2 of our India lists: Momentum stocks and Small & mid cap stocks.

Dr Lal Pathlabs Ltd earned ₹194 Cr of net profit in the Sep 2026 quarter, +27.6% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹510 Cr. Over 10 years profit has grown 14.4% a year on average. That is 22.2% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹152 Cr.

For the full year, FY26 profit was ₹510 Cr (+3.7% on the year before).

Why profit moved: revenue changed +19.6% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +8.0% and revenue +16.5%. Profit is growing slower than sales: rising costs are taking part of the growth.

FY26-Q4. revenue ₹703 Cr and profit ₹132 Cr as reported.

FY27-Q1. revenue ₹798 Cr and profit ₹170 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Dr Lal Pathlabs Ltd reported ₹874 Cr of revenue in the Sep 2026 quarter, +19.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 13.3% a year on average. The last full year, FY26, came in at ₹2,763 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹3,035 Cr.

FY26 revenue was ₹2,763 Cr, +12.3% on the year before.

Recent pace: the last four quarters grew +16.5% on average, against 13.3% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +16.7%, against +13.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +8.7%, against +20.1% a year (rolling over).

FY26-Q4. revenue ₹703 Cr and profit ₹132 Cr as reported.

FY27-Q1. revenue ₹798 Cr and profit ₹170 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Dr Lal Pathlabs Ltd's operating margin was 32.0% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 24.0% and 28.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Patient volume increased 8.2% YoY and samples increased 10.7% to 25.9 million. Management retains a 6-7% starting-year patient-volume view and will reassess after Q2 or H1, so one quarter does not establish a permanent acceleration.

Why the margin moved: operating margin changed +1.4 percentage points on the year while gross margin changed +0.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

FY26-Q4. revenue ₹703 Cr and profit ₹132 Cr as reported.

FY27-Q1. revenue ₹798 Cr and profit ₹170 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Over the last 3 years, 128% of Dr Lal Pathlabs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹636 Cr of operating cash against ₹510 Cr of profit. After ₹254 Cr of spending on assets, ₹382 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 128% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Dr Lal Pathlabs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −79 days in FY26, down from −78 days in FY21. It spent ₹401 Cr on assets over the last 3 years. Customers take 15 days to pay, and stock sits for 30 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,763 Cr, each day of that cycle ties up about ₹7.6 Cr, so roughly −₹598 Cr is tied up in the business at any time.

FY26: customers took 15 days to pay and stock sat for 30 days, about 1.0 months of sales sitting as stock, for a full cycle of −79 days, shorter than FY21's −78.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 30 days. Customers pay about 15 days after that. Suppliers are paid at 123 days. Together that makes the −79-day cycle.

Spending on assets: ₹401 Cr over the last 3 years, against ₹448 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹7.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Dr Lal Pathlabs Ltd's P/E is 54.5×, in the middle of its own history: higher than 47% of past readings. Its usual P/E (the middle reading) is 55.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹34.90.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.